Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Intravenous Infusions of PF-07304814 (Lufotrelvir) in Participants Hospitalized With COVID-19

BACKGROUND: An urgent need remains for antiviral therapies to treat patients hospitalized with COVID-19. PF-07304814—the prodrug (lufotrelvir) and its active moiety (PF-00835231)—is a potent inhibitor of the SARS-CoV-2 3CL protease. METHOD: Eligible participants were 18 to 79 years old and hospitali...

Descripción completa

Detalles Bibliográficos
Autores principales: Robinson, Philip, Toussi, Sima S, Aggarwal, Sudeepta, Bergman, Arthur, Zhu, Tong, Hackman, Frances, Sathish, Jean G, Updyke, Lawrence, Loudon, Peter, Krishna, Ganesh, Clevenbergh, Philippe, Hernandez-Mora, Miguel Gorgolas, Cisneros Herreros, Jose Miguel, Albertson, Timothy E, Dougan, Michael, Thacker, Amber, Baniecki, Mary Lynn, Soares, Holly, Whitlock, Mark, Nucci, Gianluca, Menon, Sandeep, Anderson, Annaliesa S, Binks, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10407246/
https://www.ncbi.nlm.nih.gov/pubmed/37559753
http://dx.doi.org/10.1093/ofid/ofad355

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10407246/
https://www.ncbi.nlm.nih.gov/pubmed/37559753
http://dx.doi.org/10.1093/ofid/ofad355

Ejemplares similares